Brokerages expect Equillium, Inc. (NASDAQ:EQ) to post earnings per share (EPS) of ($0.34) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Equillium’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.32). Equillium reported earnings per share of ($0.31) during the same quarter last year, which indicates a negative year over year growth rate of 9.7%. The firm is scheduled to announce its next earnings results on Tuesday, November 9th.
On average, analysts expect that Equillium will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.40) to ($1.19). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.71) to ($1.09). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Equillium.
Equillium (NASDAQ:EQ) last posted its quarterly earnings data on Tuesday, August 10th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.01.
NASDAQ EQ traded down $0.14 on Friday, hitting $5.84. 924 shares of the stock were exchanged, compared to its average volume of 94,275. Equillium has a 52-week low of $3.47 and a 52-week high of $11.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 19.99 and a quick ratio of 19.99. The company has a market capitalization of $171.58 million, a price-to-earnings ratio of -4.63 and a beta of 1.49. The company’s 50-day moving average price is $6.09 and its two-hundred day moving average price is $6.13.
In other Equillium news, insider Stephen Connelly sold 8,092 shares of the business’s stock in a transaction on Wednesday, October 6th. The shares were sold at an average price of $7.01, for a total transaction of $56,724.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jason A. Keyes sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 27th. The shares were sold at an average price of $5.72, for a total transaction of $28,600.00. Following the transaction, the chief financial officer now directly owns 17,711 shares of the company’s stock, valued at approximately $101,306.92. The disclosure for this sale can be found here. Insiders sold 21,092 shares of company stock valued at $139,245 over the last quarter. 32.70% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of EQ. Geode Capital Management LLC increased its stake in Equillium by 99.0% in the first quarter. Geode Capital Management LLC now owns 129,072 shares of the company’s stock valued at $922,000 after acquiring an additional 64,200 shares during the period. Northern Trust Corp grew its stake in Equillium by 42.9% during the first quarter. Northern Trust Corp now owns 34,055 shares of the company’s stock worth $243,000 after buying an additional 10,228 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Equillium during the first quarter worth about $1,817,000. Citadel Advisors LLC bought a new stake in Equillium during the first quarter worth about $153,000. Finally, Millennium Management LLC grew its stake in Equillium by 413.3% during the first quarter. Millennium Management LLC now owns 63,012 shares of the company’s stock worth $451,000 after buying an additional 50,736 shares during the last quarter. 24.20% of the stock is currently owned by institutional investors and hedge funds.
Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.
Recommended Story: What are the benefits of buying treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.